Anixa is focused on the treatment and prevention of cancer and infectious diseases.

Anixa Biosciences, Inc. is developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease.  Anixa’s oncology programs are using the body’s immune system to take multiple approaches in fighting cancer—developing treatments and vaccines.  Anixa’s infectious disease program consists of a treatment for COVID-19 focused on inhibiting certain protein function necessary for viral replication.



We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.


We are developing a treatment for COVID-19 that is designed to inhibit protein function necessary for replication of SARS-CoV-2, the virus causing the disease.


Breast Cancer Vaccine

We are developing a revolutionary vaccine technology focused on preventing breast cancer, specifically triple negative breast cancer, the most lethal form of the disease.

Ovarian Cancer Vaccine

Using a similar mechanism of action as our breast cancer vaccine technology, we are developing a vaccine to prevent the occurrence of ovarian cancer.

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference


Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant


Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study


Stock Data

View Investors Relations
Nasdaq: ANIX